HK inno.N Obtains Product Approval for Influenza Treatment 'Peramix Injection'
HK inno.N announced on the 24th that it has received product approval from the Ministry of Food and Drug Safety for its new influenza treatment, 'Peramix Injection.' With this approval, HK inno.N has secured new competitiveness in the influenza treatment market.
The newly approved 'Peramix Injection' is characterized by its development as an IV bag formulation, unlike existing injectable forms. It is designed to be more convenient and efficient for medical staff to administer to patients in clinical settings.
With recent recurring influenza outbreaks, the demand for treatments is steadily increasing. Therefore, the launch of this new product is expected to provide patients with a wider range of treatment options and contribute to a stable supply of medicine during the flu season.
Based on this approval, HK inno.N plans to begin full-scale market penetration. Industry attention is now focused on the impact this treatment will have on the domestic influenza treatment landscape.